Study on Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Have a confirmed diagnosis of stages IB, II, or III (N2) Non-Small Cell Lung Cancer (NSCLC) that can be surgically removed.
• Have measurable cancer as defined by specific medical criteria.
• Have known PD-L1 expression.
• Do not have known EGFR mutations or ALK fusions.
• Be 18 years or older.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have not received any prior therapy for lung cancer.
• Have adequate organ and bone marrow function as determined by specific blood tests.
• Women of childbearing potential must have a negative pregnancy test before starting the study.
• Agree to use effective contraception during the study and for six months after the last treatment.
• Men must agree not to donate sperm during the study and for six months after the last treatment.

Exclusion Criteria

• Have a history of another primary cancer, except for certain treated cancers with no active disease for at least two years.
• Have used immunosuppressive medication within 14 days before starting Cemiplimab, with some exceptions.
• Have active or prior autoimmune or inflammatory disorders, with some exceptions.
• Have uncontrolled illnesses, such as infections requiring antibiotics, heart failure, or psychiatric conditions that would interfere with the study.
• Have interstitial lung disease or active pneumonitis requiring treatment with steroids.
• Have received a live vaccine within 30 days before starting the study medication.
• Have had a stem cell or organ transplant.
• Have known HIV, active hepatitis B, or C.
• Are pregnant or breastfeeding.
• Are unwilling to use highly effective contraception during the study and for six months after the last treatment.